Details of the Drug Combinations

General Information of This Drug (ID: DMD2WPG)

Drug Name

TRIENTINE DMD2WPG

Synonyms

Trientine HCl; 21121-06-2; triethylenetetramine HCl; SMR000058543; AC1NUQ0M; MLS000069683; SCHEMBL205201; CHEMBL1200783; CTK0I9735; DTXSID80419994; XPVOJYDIBHYVFL-UHFFFAOYSA-N; Pharmakon1600-01505675; NSC759164; NSC158271; AKOS027276425; NSC-158271; NSC-759164; 1, N,N'-bis(2-aminoethyl)-, tetrahydrochloride; 1,2-Ethanediamine, N,N'-bis(2-aminoethyl)-, hydrochloride; N'-[2-(2-aminoethylamino)ethyl]ethane-1,2-diamine hydrochloride

Indication

Disease Entry	ICD 11	Status	REF
Inborn error of metabolism	5C50-5C59	Approved	[1]
Wilson disease	5C64.00	Investigative	[2]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Trientine + Carboplatin	DCTFFT1	Carboplatin	Advanced Cancers	[3]
------------------------------------------------------------------------------------

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	Trientine FDA Label
3	ClinicalTrials.gov (NCT01178112) Trientine and Carboplatin in Advanced Malignancies